A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma
- 1 September 2002
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 16 (6) , 379-382
- https://doi.org/10.1002/bmc.166
Abstract
Flavopiridol is an inhibitor of cyclin-dependent kinase, a key regulator of cell cycle, and is currently under clinical trials. We developed and validated an HPLC assay method for the quantitation of flavopiridol in human plasma samples. The sample preparation consisted of protein precipitation with acetonitrile. Separation was accomplished on a C(18) column and a C(18) precolumn insert utilizing a gradient profile consisting of ammonium acetate and methanol. Ultraviolet detection was set at 268 nm for flavopiridol and 323 nm for umbelliferone, the internal standard. The method was validated over flavopiridol concentration range of 0.025-3.0 microg/mL using 250 microL of plasma. The assay was linear over this concentration range with a coefficient of variation less than 10% for inter- and intra-assay. The retention times were around 6.2 min for umbelliferone and 9.8 min for flavopiridol. The recoveries of flavopiridol and umbelliferone were 88.6 +/- 1.0% and 97.1 +/- 3.7%, respectively. This method is suitable for quantifying flavopiridol in plasma samples and further characterizing the clinical pharmacology of this compound.Keywords
This publication has 5 references indexed in Scilit:
- Preclinical and Clinical Development of Cyclin-Dependent Kinase ModulatorsJNCI Journal of the National Cancer Institute, 2000
- Flavopiridol, A Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium StudyJournal of Clinical Oncology, 2000
- Cyclin-Dependent KinasesInitial Approaches to Exploit a Novel Therapeutic TargetPharmacology & Therapeutics, 1999
- Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.Journal of Clinical Oncology, 1998
- Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detectionCancer Chemotherapy and Pharmacology, 1998